Medicare Enrolled
Dr. Philip Mayo, M.D.
Pulmonary Disease · Goldsboro, NC
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mayo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mayo?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mayo
Dr. Philip Mayo is a pulmonary disease specialist in Goldsboro, NC, with 20 years of NPI registration. Based on federal Medicare data, Dr. Mayo performed 1,132 Medicare services across 794 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mayo received a total of $5,271 from 65 pharmaceutical and/or device companies across 301 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mayo is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 29% volume in NC
$5,271 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,132
Medicare services
Top 29% in NC for pulmonary disease
794
Unique beneficiaries
$85
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~57 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
220 | $165 | $529 |
| EKG interpretation and report A standard electrocardiogram test that records the heart's electrical activity using at least 12 leads. The service includes a professional interpretation of the results and a written report. |
169 | $6 | $31 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
166 | $67 | $181 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
125 | $93 | $215 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
113 | $87 | $254 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
110 | $113 | $357 |
| Airflow rate measurement test A test that measures the rate of airflow. This procedure assesses how quickly air moves. |
44 | $29 | $134 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
43 | $133 | $392 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
30 | $40 | $187 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
30 | $41 | $192 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
29 | $83 | $267 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
25 | $28 | $121 |
| Insertion of non-tunneled central venous catheter A procedure to place a central venous catheter for infusion in patients aged 5 years or older. The catheter is inserted directly into a large vein without being tunneled under the skin. |
14 | $65 | $367 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
14 | $6 | $100 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.2% high complexity
0.0% medium
98.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,271
Total received (2018-2024)
Avg $753/year across 7 years
Top 32% in NC for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
65
Companies
301
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,271 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,458
2023
$859
2022
$748
2021
$650
2020
$449
2019
$579
2018
$527
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Lundbeck LLC
$185
ABBVIE INC.
$175
Merck Sharp & Dohme LLC
$105
Neurelis, Inc.
$101
GlaxoSmithKline, LLC.
$99
Alexion Pharmaceuticals, Inc.
$73
GENZYME CORPORATION
$71
BANNER LIFE SCIENCES, LLC
$60
Neurocrine Biosciences, Inc.
$53
Lilly USA, LLC
$53
Aucta Pharmaceuticals, Inc.
$51
Regeneron Healthcare Solutions, Inc.
$49
RECORDATI_RARE_DISEASES_INC.
$44
Bayer Healthcare Pharmaceuticals Inc.
$42
Novo Nordisk Inc
$34
TG Therapeutics, Inc.
$31
ARGENX US, INC.
$29
Baxter Healthcare
$26
UCB, Inc.
$22
SCILEX PHARMACEUTICALS INC.
$21
Abbott Laboratories
$21
CeQur Corporation
$20
Insmed, Inc.
$20
Biogen, Inc.
$20
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
Inspire Medical Systems, Inc.
$18
Phathom Pharmaceuticals, Inc.
$15
Top 3 companies account for 31.9% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$515
Genentech USA, Inc.
$431
Teva Pharmaceuticals USA, Inc.
$341
ABBVIE INC.
$264
Lundbeck LLC
$244
Alexion Pharmaceuticals, Inc.
$230
Novartis Pharmaceuticals Corporation
$200
Neurocrine Biosciences, Inc.
$185
AstraZeneca Pharmaceuticals LP
$168
Regeneron Healthcare Solutions, Inc.
$162
Merck Sharp & Dohme LLC
$160
Boehringer Ingelheim Pharmaceuticals, Inc.
$152
Mallinckrodt Hospital Products Inc.
$120
Neurelis, Inc.
$118
Lilly USA, LLC
$109
SK Life Science, Inc.
$109
Merck Sharp & Dohme Corporation
$103
EMD Serono, Inc.
$95
GENZYME CORPORATION
$91
BANNER LIFE SCIENCES, LLC
$84
Grifols USA, LLC
$69
Supernus Pharmaceuticals, Inc.
$68
Allergan Inc.
$65
UCB, Inc.
$62
Celgene Corporation
$54
Aucta Pharmaceuticals, Inc.
$51
Baxter Healthcare
$51
Novo Nordisk Inc
$50
EISAI INC.
$50
Insmed, Inc.
$46
RECORDATI_RARE_DISEASES_INC.
$44
AbbVie Inc.
$44
Amgen Inc.
$43
Biogen, Inc.
$43
Bayer Healthcare Pharmaceuticals Inc.
$42
Biohaven Pharmaceutical Holding Company Ltd.
$32
TG Therapeutics, Inc.
$31
Avanir Pharmaceuticals, Inc.
$31
Janssen Pharmaceuticals, Inc
$30
ARGENX US, INC.
$29
Biohaven Pharmaceuticals, Inc.
$29
Mylan Specialty L.P.
$28
Kyowa Kirin, Inc.
$23
Actelion Pharmaceuticals US, Inc.
$23
SCILEX PHARMACEUTICALS INC.
$21
ADVANCED RESPIRATORY, INC
$21
Abbott Laboratories
$21
CeQur Corporation
$20
Circassia Pharmaceuticals Inc
$20
Dexcom, Inc.
$19
Takeda Pharmaceuticals U.S.A., Inc.
$19
Inspire Medical Systems, Inc.
$18
Avion Pharmaceuticals
$18
IMPEL PHARMACEUTICALS INC.
$17
Eisai Inc.
$17
Amneal Pharmaceuticals LLC
$16
Aprecia Pharmaceuticals, LLC
$16
Amarin Pharma Inc.
$16
Philips Electronics North America Corporation
$15
Phathom Pharmaceuticals, Inc.
$15
PFIZER INC.
$14
Mallinckrodt Enterprises LLC
$14
BioDelivery Sciences International, Inc.
$12
LivaNova USA, Inc.
$11
Inogen, Inc.
$9
Top 3 companies account for 24.4% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · AJOVY · ANORO · ANORO ELLIPTA · AREXVY · AUSTEDO · AVYCAZ · Aimovig · Arikayce · Austedo XR · BAFIERTAM · BELBUCA · BELSOMRA · BREO · BRIUMVI · CINQAIR · CeQur Simplicity · Crysvita · DIFICID · DUPIXENT · Dayvigo · Dexcom G6 Transmitter · Dhivy · ELIQUIS · EMGALITY · Esbriet · FASENRA · Fycompa · GLASSIA · Hillrom - Life 2000 Ventilation System · INGREZZA · INSPIRE · InogenOne · JANUVIA · JARDIANCE · KESIMPTA · KEYTRUDA · Kerendia · MAVENCLAD · MOUNJARO · Motpoly XR · NUCALA · NUEDEXTA · NURTEC ODT · Nayzilam · OFEV · OPSUMIT · OXTELLAR XR · Ongentys · Ozempic · PROCLAIM · Prolastin-C · Prolastin-C Liquid · QULIPTA · RYTARY · SIGNIFOR LAR · STIOLTO RESPIMAT · SYMBICORT · Soliris · Spritam · TRADJENTA · TRELEGY ELLIPTA · TROKENDI XR · TUDORZA PRESSAIR · TYSABRI · The Vest System Model 105 Home Care · Trudhesa · UBRELVY · ULTOMIRIS · Ultomiris · VALTOCO · VNS Therapy · VOQUEZNA · VUMERITY · VYEPTI · VYVGART · Vascepa · Vimpat · XOLAIR · Xolair · Yupelri · ZEPOSIA · ZERBAXA · ZTLido
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
7
Per 100K population
6.0
County median income
$58,082
Nearest hospital
UNC HEALTH CARE WAYNE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mayo is a clinical cardiology specialist, with above-average Medicare volume (top 29% in NC), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mayo experienced with critical care, first 30-74 min?
Based on Medicare claims data, Dr. Mayo performed 220 critical care, first 30-74 min services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mayo receive payments from pharmaceutical companies?
Yes. Dr. Mayo received a total of $5,271 from 65 companies across 301 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mayo's costs compare to other pulmonary diseases in Goldsboro?
Dr. Mayo's average Medicare payment per service is $85. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mayo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Goldsboro
Browse pulmonary diseases in Goldsboro ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NC
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NC
Which NC pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
Teva Pharmaceuticals USA, Inc. Payments to Doctors
See all physicians who received payments from Teva Pharmaceuticals USA, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology